Novartis broadens cancer immune therapy pipeline with acquisition, licensing pacts
Wednesday, October 21, 2015
Novartis said it broadened its immuno-oncology pipeline with the acquisition of Admune Therapeutics and licensing agreements with Xoma and Palobiofarma.
Palobiofarma, a Spanish biotech, said separately it entered into a $15 million licensing agreement with the Swiss company.
Novartis said in a statement that these transactions add IL-15, adenosine receptor and tgf-beta inhibition programs to the Basel-based company's immuno-oncology portfolio.
reuters.com
